Who are Seretide 250/placebo via Synchro-Breathe's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/seretide-250-placebo-via-synchro-breathe.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Seretide 250/placebo via Synchro-Breathe — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Seretide 250/placebo via Synchro-Breathe (Seretide 250/placebo via Synchro-Breathe) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination inhaled corticosteroid and long-acting beta-2 agonist (ICS/LABA). Area: Respiratory/Pulmonology.

marketed Combination inhaled corticosteroid and long-acting beta-2 agonist (ICS/LABA) Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol) Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Seretide 250/placebo via Synchro-Breathe (Seretide 250/placebo via Synchro-Breathe) — Brian J Lipworth. Seretide combines fluticasone propionate (inhaled corticosteroid) and salmeterol (long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Seretide 250/placebo via Synchro-Breathe TARGET	Seretide 250/placebo via Synchro-Breathe	Brian J Lipworth	marketed	Combination inhaled corticosteroid and long-acting beta-2 agonist (ICS/LABA)	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination inhaled corticosteroid and long-acting beta-2 agonist (ICS/LABA) class)

Brian J Lipworth · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Seretide 250/placebo via Synchro-Breathe — Competitive Intelligence Brief. https://druglandscape.com/ci/seretide-250-placebo-via-synchro-breathe. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab